TXNIP and breast carcinoma: Hitherto, future studies are warranted to assess whether hyperglycemia-induced TXNIP/TRX/ROS biology is a prerogative of MDA-MB-231 cells or it extends to other breast cancer-derived cell lines independently from their hormonal receptor status (estrogen receptors) or signaling pathways (ras mutations, p38 MAKP milieu, etc.).